Af­ter rocky hep C path, Achillion finds sur­er foot­ing with FDA break­through sta­tus

Achillion’s promis­ing proof-of-con­cept da­ta for its lat­est drug has won break­through sta­tus at the FDA.

The US reg­u­la­tor grant­ed its cov­et­ed des­ig­na­tion to dan­i­co­pan as a treat­ment for ane­mia in parox­ys­mal noc­tur­nal he­mo­glo­bin­uria pa­tients tak­ing the main­line C5 in­hibitor treat­ment Soliris. Up to 75% of PNH pa­tients suf­fer from ane­mia even af­ter treat­ment, ac­cord­ing to Achillion, with up to a third re­quir­ing blood trans­fu­sions in the past year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER